- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Vivus (VVUS) Reports Encouraging Results Of Erectile Dysfunction Drug Trials
Recent Articles by Ed Liston
- Ritchie Bros. Auctioneers’ (RBA) Price Target Lowered
- Harman International Industries, Inc. (HAR) Price Target Raised
- EV Energy Partners, L.P.’s (EVEP) Price Target Raised
- Electronic Arts, Inc.’s (ERTS) Price Target Lowered
- Coeur d’Alene Mines Corporation’s (CDE) Price Target Lowered
Company News
- TheStreet.com (TSCM) Gains Nasdaq Listing Compliance
- Vale Surging On High Volume (VALE)
- Google Takes on Facebook and Twitter
- FBR Gets Market Perform On SAP
- Morgan Stanley Ups Rockwell To Equal Weight
Markets
- TheStreet.com (TSCM) Gains Nasdaq Listing Compliance
- Stocks That Created New 52-Week Highs (CPTS, CPEX, DMND, FORR, LNCR)
- Benzinga's Intra-Day Gainers (UAUA, AMR, CMP, DB)
- Benzinga’s Volume Movers (ACLI, VECO, SWIR, LNCR, TISI)
- Benzinga’s Volume Movers (ACLI, VECO, SWIR, LNCR, TISI)
Tech
Posted on 11/19/09 at 9:27am by Ed Liston
VIVUS, Inc. (NASDAQ: VVUS) has reported encouraging clinical trials of its new erectile dysfunction drug that it is developing. The company has reported that the drug was able to show results in less than half an hour thereby meeting the goals of the Phase 3 trials.
The company conducted tests on 646 patients and found that almost three quarters were ready for sexual intercourse within 30 minutes of taking the new drug Avanafil which is being tested out. This drug helps to inhibit PDE5 enzyme, which causes erectile dysfunction. The same enzyme is also attacked by well known drugs Viagra and Cialis. But the action of Avanafil is designed to be faster than its better known competitors.
The drug also has no serious side effects while some of the most common side effects are that of flushing and headaches, which are present in all erectile dysfunction drugs. VIVUS, Inc. wants to file for regulatory approval late 2010 or early 2011.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
There are 1 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Avanafil is not the only
by Avanafil on 01/06/10 1:39pm
Avanafil is not the only medication that Vivus is working on. Vivus is also working on Qnexa, which was recently submitted to the FDA for the treatment of Obesity. Also, based
on VVUS technical analysis alone, it looks like it has formed a flag and pennant and seemingly has broken above the trend. VVUS could be a good pick right now.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
